All In Biotech

NDA 217347 · Botanix Sb

Sofdra

Sofpironium Bromide · Topical

Novel

CDER novel approval, Jun 18, 2024: To treat primary axillary hyperhidrosis

Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 18, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

3 Phase 3, 0 recruiting

FAERS reports

281

34 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2025.

SOFDRA is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. SOFDRA is an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).

Mechanism: Sofpironium bromide is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of these receptors.

Therapeutic areas: Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 18, 2024 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • SOFDRA · SOFPIRONIUM BROMIDE EQ 12.45% BASE (EQ 72MG BASE/ACTUATION) · GEL, METERED, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sofpironium" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vision blurred102
  • dry mouth63
  • application site pain39
  • mydriasis31
  • application site irritation26
  • drug ineffective24
  • rash24
  • application site rash23
  • urinary retention23
  • off label use14
  • dysuria12
  • application site erythema10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20242
2025130
2026149

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Botanix Sb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.